Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt ...

She has resigned from the former; the latter does not matter since 23andMe’s equity could be wiped out. If persistence pays off, a company that started out as little more than an intriguing idea and a ...

Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes ...

Bengaluru: Mallinckrodt and Endo , drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes John George for the Philadelphia Business Journal ...

Below we explain how we will communicate with you. We set out how we use your data in our Privacy Policy. Global City Media, and its associated brands will use the ...

Pharmaceutical companies Mallinckrodt Pharmaceuticals Plc and Endo Inc. have signed an agreement to create a combined company worth $6.7 billion. This is reported in a joint press release. Under the ...

Mallinckrodt plc and Endo, Inc. announced that they have entered into a definitive agreement to combine in a stock and cash transaction to create a global, scaled, diversified pharmaceuticals leader.

Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and US opioid litigation, have agreed to merge in a deal valued at nearly $7 billion. Endo shareholders will get $80 ...

DUBLIN and MALVERN, Pa. - Mallinckrodt plc and Endo International plc announced a definitive merger agreement in a stock and cash transaction. The deal is set to create a global pharmaceuticals leader ...